Evidence map›Paper›PMID 34281720›Full record

ReviewMolecular aspects of medicine2022

Revealing macropinocytosis using nanoparticles.

Nicolas Means, Chandra Kumar Elechalawar, Wei R Chen, Resham Bhattacharya, Priyabrata Mukherjee

Open access · greenAbstract readReview
In one paragraph

Review in Molecular aspects of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nicolas MeansDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Chandra Kumar ElechalawarDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Wei R ChenStephenson School of Biomedical Engineering, Gallogly College of Engineering, University of Oklahoma, Norman, OK, 73019, USA.
Resham BhattacharyaPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Priyabrata MukherjeeDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: Priyabrata-Mukherjee@ouhsc.edu.
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Molecular Mechanism of Antiangiogenic Properties of Gold NanoparticleR01CA136494 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2009 to 2020
$2.9M
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery systemR01CA253391 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2021 to 2025
$1.7M
Reprogramming Tumor Microenvironment by NanoparticleR01CA213278 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2017 to 2021
$1.7M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancersR01CA205348 · NCI · UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · 2017 to 2021
$1.5M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA136494NCI NIH HHS R01 CA205348NCI NIH HHS R01 CA213278NCI NIH HHS R01 CA253391NCI NIH HHS R01 CA260449
6 · The paper itself

Abstract

Endocytosis mechanisms are one of the methods that cells use to interact with their environments. Endocytosis mechanisms vary from the clathrin-mediated endocytosis to the receptor independent macropinocytosis. Macropinocytosis is a niche of endocytosis that is quickly becoming more relevant in various fields of research since its discovery in the 1930s. Macropinocytosis has several distinguishing factors from other receptor-mediated forms of endocytosis, including: types of extracellular material for uptake, signaling cascade, and niche uses between cell types. Nanoparticles (NPs) are an important tool for various applications, including drug delivery and disease treatment. However, surface engineering of NPs could be tailored to target them inside the cells exploiting different endocytosis pathways, such as endocytosis versus macropinocytosis. Such surface engineering of NPs mainly, size, charge, shape and the core material will allow identification of new adapter molecules regulating different endocytosis process and provide further insight into how cells tweak these pathways to meet their physiological need. In this review, we focus on the description of macropinocytosis, a lesser studied endocytosis mechanism than the conventional receptor mediated endocytosis. Additionally, we will discuss nanoparticle endocytosis (including macropinocytosis), and how the physio-chemical properties of the NP (size, charge, and surface coating) affect their intracellular uptake and exploiting them as tools to identify new adapter molecules regulating these processes.

Indexed as

ClathrinNanoparticlesBiological TransportEndocytosisHumansPinocytosisClathrinCaveolin-mediated endocytosisClathrin-mediated endocytosisEndocytosisMacropinocytosisNanoparticle

Identifiers

PMID34281720
PMCPMC8761201
OpenAlexW3185753590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.